Acute Myeloid Leukemia | Tumor

CURE’s acute myeloid leukemia page features the latest cancer news and updates on acute myeloid leukemia. Through articles, videos, podcasts, and more, CURE brings readers the insights of experts, cancer survivors, patients, and advocates to ensure everyone is up to date in acute myeloid leukemia.

FDA Approves Tibsovo, First IDH1 Inhibitor for Acute Myeloid Leukemia

July 20th 2018, 8:51pm

Article

Today's approval of Tibsovo, along with the diagnostic tool to determine who should get it, brings a new type of treatment for patients with acute myeloid leukemia.

Genetic Mutation Can Predict Acute Myeloid Leukemia Risk a Decade Before Diagnosis

July 17th 2018, 8:23pm

Article

While there are known risk factors of developing acute myeloid leukemia (AML) – such as a myelodysplastic syndrome diagnosis and receiving chemotherapy and radiotherapy – a diagnosis can still stun and individual. But researchers at Weill Cornell Medicine and New York-Presbyterian recently discovered a genomic pre-malignant biomarker of the disease that can identify people who are at a greater risk for AML.

Novel Drug Granted Priority Review for Acute Myeloid Leukemia Treatment

June 27th 2018, 9:11pm

Article

The Food and Drug Administration (FDA) has granted a priority review to a new drug application (NDA) for glasdegib to treat patients with previously untreated acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC), which is a type of chemotherapy, according to Pfizer, the manufacturer of the drug.

FDA Grants Gilteritinib a Priority Review for Acute Myeloid Leukemia Treatment

May 29th 2018, 7:42pm

Article

The Food and Drug Administration (FDA) has granted a priority review to a new drug application (NDA) for gilteritinib for the treatment of adult patients with FLT3 mutation–positive relapsed or refractory acute myeloid leukemia (AML), according to Astellas Pharma, the manufacturer of the FLT3 inhibitor.

On Jackie Robinson and Bone Marrow Transplants

May 18th 2018, 4:09am

Article

“A life is not important except in the impact it has on other lives.”

NCI-Designated Cancer Centers Yield Improved Mortality Rates in Acute Myeloid Leukemia

May 3rd 2018, 5:21pm

Article

As suspected, the average early mortality rate improved overall during the study period. But while evaluating the data, researchers noticed something interesting about the difference in early mortality at the NCI-designated cancer centers compared to non-NCI-designated cancer centers.

Lab of Plenty: New Drugs Bring Hope for AML Treatment

February 23rd 2018, 12:10am

Article

New drugs bring advancements to acute myeloid leukemia after 40 years.

Ivosidenib Granted FDA Priority Review for AML Treatment

February 15th 2018, 11:25pm

Article

Ivosidenib (AG-120) was granted a priority review designation by the Food and Drug Administration (FDA) for the treatment of patients with relapsed/refractory IDH1-mutant acute myeloid leukemia (AML), according to a statement from Agios Pharmaceuticals, the company developing the targeted therapy.

Older Adults with AML Don't Understand the Risks and Likely Outcomes of Treatment

October 24th 2017, 4:20am

Article

Older patients with acute myeloid leukemia (AML) often face a difficult choice: risky, intensive chemotherapy that offers a small chance of a cure versus non-intensive chemotherapy meant to improve physical comfort and quality of life.

FDA Approves Rydapt for AML

April 28th 2017, 11:10pm

Article

The Food and Drug Administration has approved Rydapt (midostaurin) for acute myeloid leukemia (AML).